MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update.

摘要: Diabetic kidney disease (DKD) is a life-limiting condition characterized by progressive and irreversible loss of renal function. Currently, the estimated glomerular filtration rate (eGFR) albuminuria are used as key markers to define DKD. However, they may not accurately indicate degree dysfunction injury. Current therapeutic approaches for DKD, including attainment blood pressure goals, optimal control glucose lipid levels, use agents block renin-angiotensin-aldosterone system (RAAS) can only slow progression Hence, early diagnosis innovative strategies needed both prevent treat In recent years, novel class noncoding RNA, microRNAs (miRNAs) reported be involved in all biological processes, cellular proliferation, apoptosis, differentiation. miRNAs small RNAs that regulate gene expression posttranscriptional epigenetic mechanisms. They found virtually body fluids successfully biomarkers various diseases. Urinary correlate with clinical histologic parameters DKD differential urinary miRNA patterns have been reported. Kidney fibrosis common end stage CKD Transforming growth factor-β(TGF-β) regarded master regulator fibrosis, which likely at least part through regulating expression. widely via many molecular this review, involvement inflammation, hypertrophy, autophagy, endoplasmic reticulum (ER) stress, oxidative insulin resistance, podocyte injury will discussed, these mechanisms believed offer new targets exploited develop important treatments over next decade.